Tumor Blood Testing Market, By Biomarker Type (Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs), Extracellular Vehicles (EVs)/Exosomes, and Other Cell-Free Nucleic Acids), By Technology (Polymerase Chain Reaction (PCR)-Based Testing, Next-Generation Sequencing (NGS), Microarray-Based Testing, Mass Spectrometry, and Immunoassays), By Clinical Application (Early Detection/Cancer Screening, Diagnosis, Therapy Selection, Treatment Monitoring, Minimal Residual Disease (MRD) Detection, and Recurrence Monitoring/Prognosis), By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer , Bladder Cancer, Melanoma, and Other Cancers (e.g., Ovarian, Pancreatic, Leukemia, Lymphoma)), By End User (Hospitals, Specialty Clinics, Diagnostic Laboratories, Academic and Research Institutes, and Pharmaceutical and Biotechnology Companies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)